文献速递浆细胞疾病造血干细胞移植与细胞治疗

抗BCMA CAR-T细胞治疗多发性骨髓瘤:能否做得更好?

Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better?
PubMed 文献 · Leukemia · 2019-11-28

本文综述抗B细胞成熟抗原(BCMA)CAR-T细胞治疗多发性骨髓瘤的临床与相关性数据。已有超过300例经重度治疗复发/难治患者数据,缓解率与缓解深度令人瞩目,但多数患者最终复发。T细胞、肿瘤及微环境因素可能影响疗效,需明确耐药机制并确定该疗法在治疗范式中的理想定位。

要点

  • 抗BCMA CAR-T在重度预处理复发/难治骨髓瘤中诱导高缓解率与深度缓解。
  • 多数患者最终复发,需阐明应答与耐药机制以理性优化治疗。
  • T细胞、肿瘤及微环境因素可能影响抗BCMA CAR-T疗效。

核心结论

  • 抗BCMA CAR-T细胞治疗在重度预处理复发/难治多发性骨髓瘤中产生前所未有的结果,但多数患者最终复发。

研究设计与样本

  • 综述总结抗BCMA CAR-T细胞治疗多发性骨髓瘤的关键临床与相关性数据,涉及超过300例患者。

主要发现

  • 抗BCMA CAR-T细胞诱导的缓解率和缓解深度令人印象深刻。
  • T细胞相关、肿瘤相关和微环境因素可能在抗BCMA CAR-T细胞治疗疗效中发挥作用。

临床怎么用

  • 需理解应答与耐药机制以合理开发该疗法,并需生物学与临床相关性数据明确其在骨髓瘤治疗范式中的理想位置。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite a substantial survival improvement and the availability of many new drugs in the last 2 decades, multiple myeloma (MM) remains largely incurable. Immunotherapeutic approaches are changing the current landscape in MM with B-cell maturation antigen (BCMA) as one of the most promising target antigens. Chimeric antigen receptor (CAR) T-cell therapy targeting BCMA produced unprecedented results in heavily pretreated relapsed and/or refractory MM. Data on more than 300 MM patients treated with anti-BCMA directed CAR T cells are available and these numbers are rapidly increasing. The response rate and the depth of responses induced by anti-BCMA CAR T cells are impressive; however, the majority of patients eventually relapse. Understanding the underlying mechanisms of response and resistance in treated MM patients will be critical to the rational development of this therapy. Moreover, the ideal place of this therapy in the treatment paradigm for MM is an important question that needs biological and clinical correlative data to help elucidate. T-cell-related, tumor-related and microenvironmental factors may play a role in the efficacy of anti-BCMA CAR T-cell therapy. In this review we summarize key clinical and correlative data on anti-BCMA CAR T-cell therapy. Based on available data we will try to highlight opportunities to further optimize this potential game-changing therapy for MM.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. D'Agostino M, Raje N. Anti-BCMA CAR T-cell therapy in multiple myeloma: can we do better? Leukemia. 2019. PMID: 31780814. doi:10.1038/s41375-019-0669-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。